Can a new drug tame Alzheimer's? early trial aims to find out
NCT ID NCT07758595
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental drug called DNL921 to see if it is safe and tolerable for people. It will involve healthy volunteers and people with Alzheimer's disease, who will receive either the drug or a placebo. The main goal is to gather safety data and understand how the drug moves through the body, which will help plan future, larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DNL921, an experimental drug being tested as a potential treatment for Alzheimer's disease
- What this could lead to
- If successful, this early trial could pave the way for a new treatment that slows or alters the course of Alzheimer's disease.
- What could go wrong
- This is a very early (Phase 1) study focused on safety and dosing, not effectiveness. The drug may not work or could have side effects, and much more research is needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Could your brain help unlock Alzheimer's secrets?
- Can a new injection help tackle obesity? a safety trial begins
- Can a gene therapy clear the toxic tau tangle in Alzheimer's?
- Will a new pill formula absorb the same? a trial puts it to the test
- Could sitting too much alter your nervous system?